<unk>  was initially approved by the U.S. Food and Drug Administration (FDA) on November 20, 2008, for the treatment of thrombocytopenia in people with chronic immune (idiopathic) thrombocytopenic purpura who have had an insufficient response to corticosteroids, immunoglobulin therapy, or splenectomy. On August 24, 2015, the FDA approved<unk>  (Promacta for oral suspension) for the treatment of thrombocytopenia in children one year and older with idiopathic thrombocytopenia who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.
Eltrombopag
Avatrombopag
Lusutrombopag
Ximelagatran
Hirudin
Tirbanibulin
Anistreplase
Desmoteplase